Ublituximab
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 118 publications
Persistent B-cell depletion after ublituximab for multiple sclerosis.
Journal: Journal of neurology
Published: July 20, 2026
Long-term efficacy and safety of ublituximab in the treatment of multiple sclerosis: A critical review of medical literature.
Journal: Multiple sclerosis and related disorders
Published: May 30, 2026
Uncoupling Relapse Reduction and Disability Progression: Evidence From Tolebrutinib Studies.
Journal: Neurology. Clinical practice
Published: May 11, 2026
Optimizing Infusion Center Efficiency in Multiple Sclerosis: A Nursing Multicenter Survey on Organizational Impact of Ublituximab.
Journal: Healthcare (Basel, Switzerland)
Published: May 05, 2026
Developing anti-CD20 molecules and B cell depletion in multiple sclerosis
Journal: Ideggyogyaszati szemle
Published: March 28, 2026
Infusion-related reactions and premedication patterns in ublituximab-treated multiple sclerosis patients: a multicenter real-world study.
Journal: Frontiers in neurology
Published: March 27, 2026
Efficacy and safety of monoclonal antibodies in the treatment of relapsing remitting multiple sclerosis: a systematic review.
Journal: Journal of neurology
Published: February 18, 2026
Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.
Journal: JAMA neurology
Published: February 16, 2026
Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap.
Journal: Clinical pharmacology and therapeutics
Published: January 31, 2026
The evolution and current status of anti-B-cell therapies in autoimmune neurologic diseases.
Journal: Handbook of clinical neurology
Published: January 12, 2026
Impact of heme on the therapeutic efficacy of anti-CD20 antibodies.
Journal: The Journal of biological chemistry
Published: January 07, 2026
Last Updated: 09/26/2026